Abstract
We previously demonstrated that dehydroevodiamine•HCl (DHED), which was purified from Evodia rutaecarpa Bentham (Rutaceae), has beneficial effects on memory impairment and neuronal damage in three disease models. To investigate the preventive action of DHED in Alzheimer’s disease (AD), a progressive neurodegenerative disorder characterized by memory decline, amyloid-β (Aβ) protein-containing neuritic plaques and neurofibrillary tangles, in this study, we proposed that DHED may be therapeutically effective against the memory impairment and disease-related neurochemical changes that occur in Tg2576 (Tg) mice. DHED (0.5 mg/kg) was intraperitoneally administered to 7-month-old Tg and wild type mice for 4 months. In passive avoidance and water maze tests, DHED improved memory impairment of Tg mice after 4 months of administration. DHED also reduced cortical levels of soluble Aβ40, soluble Aβ42 and total Aβ peptides in the Tg mice. Additionally, we investigated whether DHED may be a β-secretase inhibitor that affects the production of Aβ related to the formation of neuritic plaques. DHED directly inhibited β-secretase activity in a concentrationdependent manner. The concentration required for 50 % enzyme inhibition (IC50) was 40.96 μM, and DHED may act as a competitive inhibitor of β-secretase. Moreover, DHED interacted strongly with BACE1 (β-secretase 2QP8), as demonstrated in the analysis of the binding mode of DHED in the active site of human BACE1. In conclusion, DHED may exhibit therapeutic effects for AD as a β-secretase inhibitor.
Keywords: Alzheimer’s disease, dehydroevodiamine•HCl, memory, β-secretase, inhibitor.
CNS & Neurological Disorders - Drug Targets
Title:Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor
Volume: 15 Issue: 8
Author(s): Ki Young Shin, Su-Jin Noh, Cheol Hyoung Park, Yun Ha Jeong, Keun-A Chang, Jakyung Yoo, Hee Jin Kim, Sungji Ha, Hye-Sun Kim, Hyun-Ju Park, Jun-Ho Lee, Cheil Moon and Yoo-Hun Suh
Affiliation:
Keywords: Alzheimer’s disease, dehydroevodiamine•HCl, memory, β-secretase, inhibitor.
Abstract: We previously demonstrated that dehydroevodiamine•HCl (DHED), which was purified from Evodia rutaecarpa Bentham (Rutaceae), has beneficial effects on memory impairment and neuronal damage in three disease models. To investigate the preventive action of DHED in Alzheimer’s disease (AD), a progressive neurodegenerative disorder characterized by memory decline, amyloid-β (Aβ) protein-containing neuritic plaques and neurofibrillary tangles, in this study, we proposed that DHED may be therapeutically effective against the memory impairment and disease-related neurochemical changes that occur in Tg2576 (Tg) mice. DHED (0.5 mg/kg) was intraperitoneally administered to 7-month-old Tg and wild type mice for 4 months. In passive avoidance and water maze tests, DHED improved memory impairment of Tg mice after 4 months of administration. DHED also reduced cortical levels of soluble Aβ40, soluble Aβ42 and total Aβ peptides in the Tg mice. Additionally, we investigated whether DHED may be a β-secretase inhibitor that affects the production of Aβ related to the formation of neuritic plaques. DHED directly inhibited β-secretase activity in a concentrationdependent manner. The concentration required for 50 % enzyme inhibition (IC50) was 40.96 μM, and DHED may act as a competitive inhibitor of β-secretase. Moreover, DHED interacted strongly with BACE1 (β-secretase 2QP8), as demonstrated in the analysis of the binding mode of DHED in the active site of human BACE1. In conclusion, DHED may exhibit therapeutic effects for AD as a β-secretase inhibitor.
Export Options
About this article
Cite this article as:
Shin Young Ki, Noh Su-Jin, Park Hyoung Cheol, Jeong Ha Yun, Chang Keun-A, Yoo Jakyung, Kim Jin Hee, Ha Sungji, Kim Hye-Sun, Park Hyun-Ju, Lee Jun-Ho, Moon Cheil and Suh Yoo-Hun, Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor, CNS & Neurological Disorders - Drug Targets 2016; 15 (8) . https://dx.doi.org/10.2174/1871527315666160815163723
DOI https://dx.doi.org/10.2174/1871527315666160815163723 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Current Drug Targets Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present)
Current Topics in Medicinal Chemistry A Surgical Opinion on Hyperalgesia/Nociception, Inflammatory/Neurogenic Pain and Anti-inflammatory Responses and Drug Interventions Revisited: Current Breakthroughs and Views
Current Immunology Reviews (Discontinued) Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Monoamine Oxidases: to Inhibit or Not to Inhibit
Mini-Reviews in Medicinal Chemistry An Efficient Multiple Kernel Support Vector Regression Model for Assessing Dry Weight of Hemodialysis Patients
Current Bioinformatics A Rare Case of Azathioprine-Induced Sweet`s Syndrome in a Patient with Crohn`s Disease
Current Drug Safety Concerns and Considerations about the Quality Control of Natural Products Using Chromatographic Methods
Current Chromatography Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets New Biological Approaches in Asthma: DNA-Based Therapy
Current Medicinal Chemistry